Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Nivolumab for the treatment of small cell lung cancer.

Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Curvietto M, Ascierto PA.

Expert Rev Respir Med. 2019 Oct 17. doi: 10.1080/17476348.2020.1681977. [Epub ahead of print]

PMID:
31622114
2.

Effect of crosslinking agent to design nanostructured hyaluronic acid-based hydrogels with improved relaxometric properties.

De Sarno F, Ponsiglione AM, Grimaldi AM, Netti PA, Torino E.

Carbohydr Polym. 2019 Oct 15;222:114991. doi: 10.1016/j.carbpol.2019.114991. Epub 2019 Jun 14.

PMID:
31320060
3.

Clinical Translatability of "Identified" Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update.

Grimaldi AM, Incoronato M.

Cancers (Basel). 2019 Jun 27;11(7). pii: E901. doi: 10.3390/cancers11070901. Review.

4.

Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study.

Incoronato M, Grimaldi AM, Mirabelli P, Cavaliere C, Parente CA, Franzese M, Staibano S, Ilardi G, Russo D, Soricelli A, Catalano OA, Salvatore M.

Cancers (Basel). 2019 Jun 22;11(6). pii: E876. doi: 10.3390/cancers11060876.

5.

Biobanking in health care: evolution and future directions.

Coppola L, Cianflone A, Grimaldi AM, Incoronato M, Bevilacqua P, Messina F, Baselice S, Soricelli A, Mirabelli P, Salvatore M.

J Transl Med. 2019 May 22;17(1):172. doi: 10.1186/s12967-019-1922-3. Review.

6.

Water-Mediated Nanostructures for Enhanced MRI: Impact of Water Dynamics on Relaxometric Properties of Gd-DTPA.

De Sarno F, Ponsiglione AM, Russo M, Grimaldi AM, Forte E, Netti PA, Torino E.

Theranostics. 2019 Feb 28;9(6):1809-1824. doi: 10.7150/thno.27313. eCollection 2019.

7.

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.

Cristiani CM, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, Mallardo D, Garofalo C, Giovannone ED, Grimaldi AM, Tallerico R, Marcenaro E, Pesce S, Del Zotto G, Agosti V, Costanzo FS, Gulletta E, Rizzo A, Moretta A, Karre K, Ascierto PA, Todaro M, Carbone E.

Cancer Immunol Res. 2019 May;7(5):841-852. doi: 10.1158/2326-6066.CIR-18-0651. Epub 2019 Apr 2.

PMID:
30940644
8.

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.

Ascierto PA, Capone M, Grimaldi AM, Mallardo D, Simeone E, Madonna G, Roder H, Meyer K, Asmellash S, Oliveira C, Roder J, Grigorieva J.

J Immunother Cancer. 2019 Mar 29;7(1):91. doi: 10.1186/s40425-019-0569-1.

9.

Future perspectives of nanoparticle-based contrast agents for cardiac magnetic resonance in myocardial infarction.

Grimaldi AM, Forte E, Infante T, Cavaliere C, Salvatore M, Cademartiri F.

Nanomedicine. 2019 Apr;17:329-341. doi: 10.1016/j.nano.2019.02.003. Epub 2019 Feb 23. Review.

PMID:
30802547
10.

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA.

Oncoimmunology. 2018 Sep 5;7(12):e1405206. doi: 10.1080/2162402X.2017.1405206. eCollection 2018.

11.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA.

J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1.

12.

Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.

Incoronato M, Grimaldi AM, Cavaliere C, Inglese M, Mirabelli P, Monti S, Ferbo U, Nicolai E, Soricelli A, Catalano OA, Aiello M, Salvatore M.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1680-1693. doi: 10.1007/s00259-018-4010-7. Epub 2018 Apr 25.

PMID:
29696443
13.

DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes.

Monti S, Aiello M, Incoronato M, Grimaldi AM, Moscarino M, Mirabelli P, Ferbo U, Cavaliere C, Salvatore M.

Contrast Media Mol Imaging. 2018 Jan 17;2018:5076269. doi: 10.1155/2018/5076269. eCollection 2018.

14.

PD-L1 inhibitors in the pipeline: Promise and progress.

Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA.

Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Review.

15.

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.

Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA.

J Transl Med. 2017 Dec 4;15(1):244. doi: 10.1186/s12967-017-1348-8.

16.

Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles.

Torino E, Auletta L, Vecchione D, Orlandella FM, Salvatore G, Iaccino E, Fiorenza D, Grimaldi AM, Sandomenico A, Albanese S, Sarnataro D, Gramanzini M, Palmieri C, Scala G, Quinto I, Netti PA, Salvatore M, Greco A.

Nanomedicine. 2018 Feb;14(2):483-491. doi: 10.1016/j.nano.2017.11.016. Epub 2017 Nov 22.

PMID:
29175599
17.

Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.

Grimaldi AM, Incoronato M, Salvatore M, Soricelli A.

Nanomedicine (Lond). 2017 Oct;12(19):2349-2365. doi: 10.2217/nnm-2017-0208. Epub 2017 Sep 4. Review.

PMID:
28868980
18.

PEGylated crosslinked hyaluronic acid nanoparticles designed through a microfluidic platform for nanomedicine.

Russo M, Grimaldi AM, Bevilacqua P, Tammaro O, Netti PA, Torino E.

Nanomedicine (Lond). 2017 Sep;12(18):2211-2222. doi: 10.2217/nnm-2017-0103. Epub 2017 Aug 17.

PMID:
28814137
19.

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.

Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA.

Am J Clin Dermatol. 2017 Dec;18(6):745-754. doi: 10.1007/s40257-017-0292-y. Review.

PMID:
28537004
20.

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S.

Tumori. 2017 Sep 18;103(5):405-421. doi: 10.5301/tj.5000625. Epub 2017 May 10. Review.

PMID:
28497847
21.

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

Di Monta G, Caracò C, Simeone E, Grimaldi AM, Marone U, Di Marzo M, Vanella V, Festino L, Palla M, Mori S, Mozzillo N, Ascierto PA.

J Transl Med. 2017 Apr 26;15(1):82. doi: 10.1186/s12967-017-1186-8.

22.

Radiogenomic Analysis of Oncological Data: A Technical Survey.

Incoronato M, Aiello M, Infante T, Cavaliere C, Grimaldi AM, Mirabelli P, Monti S, Salvatore M.

Int J Mol Sci. 2017 Apr 12;18(4). pii: E805. doi: 10.3390/ijms18040805. Review.

23.

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA.

Oncoimmunology. 2017 Jan 19;6(3):e1283462. doi: 10.1080/2162402X.2017.1283462. eCollection 2017.

24.

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E.

Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242. eCollection 2017.

25.

Hybrid Core-Shell (HyCoS) Nanoparticles produced by Complex Coacervation for Multimodal Applications.

Vecchione D, Grimaldi AM, Forte E, Bevilacqua P, Netti PA, Torino E.

Sci Rep. 2017 Mar 22;7:45121. doi: 10.1038/srep45121.

26.

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Itchins M, Ascierto PA, Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A.

Melanoma Res. 2017 Jun;27(3):243-250. doi: 10.1097/CMR.0000000000000343.

PMID:
28230715
27.

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.

Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA.

BioDrugs. 2017 Feb;31(1):51-61. doi: 10.1007/s40259-016-0208-z. Review.

PMID:
28058658
28.

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.

Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozzillo N.

Cancer Immunol Immunother. 2016 Nov;65(11):1395-1400. Epub 2016 Sep 7.

PMID:
27604993
29.

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.

Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.

Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23.

30.

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

J Transl Med. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1.

31.

Single versus combination immunotherapy drug treatment in melanoma.

Grimaldi AM, Marincola FM, Ascierto PA.

Expert Opin Biol Ther. 2016;16(4):433-41. doi: 10.1517/14712598.2016.1128891. Epub 2016 Feb 6. Review.

PMID:
26642234
32.

Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial.

Grimaldi AM, Simeone E, Ascierto PA.

Melanoma Manag. 2015 Aug;2(3):209-215. doi: 10.2217/mmt.15.22. Epub 2015 Aug 10. Review.

33.

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.

Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.

Discov Med. 2015 Jun;19(107):455-61. Review.

34.

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.

Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracò C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA.

Oncoimmunology. 2015 May 22;4(6):e1008842. eCollection 2015 Jun.

35.

Electrochemotherapy in melanoma patients: a single institution experience.

Caracò C, Marone U, Simeone E, Grimaldi AM, Botti G, Del Giudice M, Ascierto PA, Mozzillo N.

Melanoma Manag. 2015 May;2(2):127-132. doi: 10.2217/mmt.15.9. Epub 2015 May 18.

36.

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series.

Di Monta G, Caracò C, Marone U, Grimaldi AM, Anniciello AM, Di Marzo M, Simeone E, Mori S.

BMC Res Notes. 2015 Apr 15;8:147. doi: 10.1186/s13104-015-1096-x.

37.

Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.

Simeone E, Grimaldi AM, Ascierto PA.

Melanoma Manag. 2015 Feb;2(1):41-50. doi: 10.2217/mmt.14.30. Epub 2015 Feb 25. Review.

38.

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.

Grimaldi AM, Simeone E, Palla M, Festino L, Caracò C, Mozzillo N, Petrillo A, Muto P, Ascierto PA.

Anticancer Drugs. 2015 Apr;26(4):464-8. doi: 10.1097/CAD.0000000000000206.

PMID:
25622086
39.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

40.

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.

Falivene S, Giugliano FM, Grimaldi AM, Di Franco R, Toledo D, Muto M, Cammarota F, Borzillo V, Ascierto PA, Muto P.

BMC Dermatol. 2014 Sep 30;14:15. doi: 10.1186/1471-5945-14-15.

41.

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA.

Oncoimmunology. 2014 May 14;3:e28780. eCollection 2014.

42.

Serious haematological toxicity during and after ipilimumab treatment: a case series.

Simeone E, Grimaldi AM, Esposito A, Curvietto M, Palla M, Paone M, Mozzillo N, Ascierto PA.

J Med Case Rep. 2014 Jul 1;8:240. doi: 10.1186/1752-1947-8-240.

43.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.

Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P.

J Exp Clin Cancer Res. 2014 Apr 4;33:30. doi: 10.1186/1756-9966-33-30.

44.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.

Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA.

Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Erratum in: Cancer Immunol Immunother. 2014 Nov;63(11):1233.

PMID:
24695951
45.

The role of MEK inhibitors in the treatment of metastatic melanoma.

Grimaldi AM, Simeone E, Ascierto PA.

Curr Opin Oncol. 2014 Mar;26(2):196-203. doi: 10.1097/CCO.0000000000000050. Review.

PMID:
24419498
46.

Marker utility for combination therapy.

Simeone E, Grimaldi AM, Ascierto PA.

Methods Mol Biol. 2014;1102:97-115. doi: 10.1007/978-1-62703-727-3_7. Review.

PMID:
24258976
47.

Novel approaches in melanoma prevention and therapy.

Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA.

Cancer Treat Res. 2014;159:443-55. doi: 10.1007/978-3-642-38007-5_25. Review.

PMID:
24114495
48.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M.

Eur J Cancer. 2014 Jan;50(1):121-7. doi: 10.1016/j.ejca.2013.09.007. Epub 2013 Oct 4.

PMID:
24100024
49.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137.

50.

Do BRAF inhibitors select for populations with different disease progression kinetics?

Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N.

J Transl Med. 2013 Mar 8;11:61. doi: 10.1186/1479-5876-11-61.

Supplemental Content

Loading ...
Support Center